Lack of sexual dimorphism in a mouse model of isoproterenol-induced cardiac dysfunction.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
04
2020
accepted:
24
06
2020
entrez:
10
7
2020
pubmed:
10
7
2020
medline:
12
9
2020
Statut:
epublish
Résumé
Sex-related differences in cardiovascular diseases are highly complex in humans and model-dependent in experimental laboratory animals. The objective of this work was to comprehensively investigate key sex differences in the response to acute and prolonged adrenergic stimulation in C57Bl/6NCrl mice. Cardiac function was assessed by trans-thoracic echocardiography before and after acute adrenergic stimulation (a single sub-cutaneous dose of isoproterenol 10 mg/kg) in 15 weeks old male and female C57Bl/6NCrl mice. Thereafter, prolonged adrenergic stimulation was achieved by sub-cutaneous injections of isoproterenol 10 mg/kg/day for 14 days in male and female mice. Cardiac function and morphometry were assessed by trans-thoracic echocardiography on the 15th day. Thereafter, the mice were euthanized, and the hearts were collected. Histopathological analysis of myocardial tissue was performed after staining with hematoxylin & eosin, Masson's trichrome and MAC-2 antibody. Gene expression of remodeling and fibrotic markers was assessed by real-time PCR. Cardiac function and morphometry were also measured before and after isoproterenol 10 mg/kg/day for 14 days in groups of gonadectomized male and female mice and sham-operated controls. In the current work, there were no statistically significant differences in the positive inotropic and chronotropic effects of isoproterenol between male and female C57Bl/6NCrl. After prolonged adrenergic stimulation, there was similar degree of cardiac dysfunction, cardiac hypertrophy, and myocardial fibrosis in male and female mice. Similarly, prolonged isoproterenol administration induced hypertrophic and fibrotic genes in hearts of male and female mice to the same extent. Intriguingly, gonadectomy of male and female mice did not have a significant impact on isoproterenol-induced cardiac dysfunction as compared to sham-operated animals. The current work demonstrated lack of significant sex-related differences in isoproterenol-induced cardiac hypertrophy, dysfunction, and fibrosis in C57Bl/6NCrl mice. This study suggests that female sex may not be sufficient to protect the heart in this model of isoproterenol-induced cardiac dysfunction and underscores the notion that sexual dimorphism in cardiovascular diseases is highly model-dependent.
Identifiants
pubmed: 32645007
doi: 10.1371/journal.pone.0232507
pii: PONE-D-20-10894
pmc: PMC7347208
doi:
Substances chimiques
Biomarkers
0
Isoproterenol
L628TT009W
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0232507Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002494
Pays : United States
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
J Am Coll Cardiol. 2017 Jul 4;70(1):1-25
pubmed: 28527533
PLoS One. 2015 May 26;10(5):e0127515
pubmed: 26010093
Chin J Physiol. 2008 Jun 30;51(3):146-51
pubmed: 18935909
Korean J Intern Med. 2015 Mar;30(2):140-7
pubmed: 25750553
JAMA. 1998 Aug 19;280(7):605-13
pubmed: 9718051
Pol Arch Intern Med. 2020 Jan 31;130(1):25-30
pubmed: 31517898
Nat Commun. 2020 Jun 2;11(1):2843
pubmed: 32487995
Biol Sex Differ. 2017 Jan 7;8:1
pubmed: 28078076
Circ Heart Fail. 2015 Jan;8(1):98-108
pubmed: 25420486
Circ Heart Fail. 2013 Jan;6(1):107-17
pubmed: 23230309
J Card Fail. 2010 May;16(5):439-49
pubmed: 20447581
J Cardiovasc Pharmacol. 2017 Sep;70(3):202-209
pubmed: 28590262
Br J Pharmacol. 2014 Feb;171(3):555-66
pubmed: 23763376
Circulation. 2004 Oct 12;110(15):2102-9
pubmed: 15466629
Biol Sex Differ. 2018 Aug 29;9(1):38
pubmed: 30157941
Circulation. 2008 Jun 24;117(25):3187-98
pubmed: 18541744
Am J Pathol. 2016 May;186(5):1114-27
pubmed: 26948424
J Card Fail. 2017 Feb;23(2):161-168
pubmed: 27663100
J Endocrinol. 2018 Mar;236(3):151-165
pubmed: 29371236
Eur J Heart Fail. 2016 Jan;18(1):8-27
pubmed: 26548803
Am J Physiol Regul Integr Comp Physiol. 2017 May 1;312(5):R835-R849
pubmed: 28274938
Am J Physiol Heart Circ Physiol. 2002 Jan;282(1):H256-63
pubmed: 11748070
Mol Med Rep. 2018 Jan;17(1):1057-1064
pubmed: 29115626
Hypertension. 1987 Feb;9(2 Pt 2):II36-9
pubmed: 3804398
J Card Fail. 2008 Apr;14(3):245-53
pubmed: 18381189
Biochem Biophys Res Commun. 2017 Jan 22;482(4):1304-1311
pubmed: 27939890
J Am Heart Assoc. 2017 Jan 23;6(1):
pubmed: 28115312
J Hypertens. 2017 May;35(5):975-981
pubmed: 28306633
J Mol Cell Cardiol. 2018 Jun;119:75-86
pubmed: 29723491
Arch Cardiovasc Dis. 2012 Feb;105(2):68-76
pubmed: 22424324
Mol Cell Biochem. 2003 Sep;251(1-2):89-95
pubmed: 14575309
Cardiooncology. 2016;2:
pubmed: 28758028
Physiol Rev. 2017 Jan;97(1):1-37
pubmed: 27807199
Curr Heart Fail Rep. 2015 Apr;12(2):187-95
pubmed: 25633565
Nat Med. 2019 Nov;25(11):1657-1666
pubmed: 31700185
Exp Cell Res. 2019 May 1;378(1):87-97
pubmed: 30853447
J Cardiovasc Pharmacol. 2019 Mar;73(3):195-205
pubmed: 30839513
J Am Coll Cardiol. 1999 Jul;34(1):264-73
pubmed: 10400020
J Cardiovasc Med (Hagerstown). 2018 Oct;19(10):527-535
pubmed: 30015781
Hypertension. 2016 Mar;67(3):606-12
pubmed: 26781273
Circ Res. 2016 Apr 15;118(8):1294-312
pubmed: 27081111
Br J Nutr. 2009 Mar;101(5):725-34
pubmed: 18590591
Endocrinology. 2012 Sep;153(9):4480-90
pubmed: 22759381
Circulation. 2003 Oct 28;108(17):2147-52
pubmed: 12963636
Am J Physiol Heart Circ Physiol. 2012 Apr 1;302(7):H1423-8
pubmed: 22307667
J Mol Cell Cardiol. 2009 Mar;46(3):360-9
pubmed: 19111554
Eur Heart J. 2019 Dec 14;40(47):3859-3868c
pubmed: 31800034
Arterioscler Thromb Vasc Biol. 2017 May;37(5):746-756
pubmed: 28279969
Am J Physiol Heart Circ Physiol. 2005 Jul;289(1):H30-6
pubmed: 15749746
Endocrinology. 2011 Dec;152(12):4937-47
pubmed: 22028441
J Cardiovasc Pharmacol. 2014 Jun;63(6):562-6
pubmed: 24477046